¿}§¿¯fµÇ¯fÅÜ

 

¬x®¶³ÇÂå®vºtÁ¿

ùºÖªQÂå®v¾ã²z

 

l          ¥xÆW¿}§¿¯f¦º¤`²v©~¨È¬w¤§«a¡A¦Ó°ê¤H¡u¦å¿}±±¨î¤£¨}¡v³Q»{¬°»P¦º¤`²vÃk¤É¦³Ãö¡]¤¤°ê®É³ø, 30 July 2004¡^¡C

l          ¥Á°ê¤E¤Q¤G¦~¤Q¤j¦º¦]¤¤¡A¿}§¿¯f¦û²Ä4¦ì¡AµÇª¢¡BµÇ¼x­Ô¸s¡BµÇÅܩʯfµ¥¦û²Ä8¦ì¡C

l          ¿}§¿¯f±w¬O¥½´ÁµÇ¯fÅÜ·s¯f¨Ò³Ì±`¨£­ì¦]¡A¤ß¦åºÞ¯e¯f­·ÀI©Ê¼W°ª2¦Ü4­¿¡A¤u§@¦~ÄÖ¼h¦¨¤H¥¢©ú·s¯f¨Òªº³Ì±`¨£­ì¦]¡A«D¥~¶Ë¤Þ°_¤UªÏºIªÏªº³Ì±`¨£­ì¦]¡C

l          ¬y¦æ¯f¾Ç

n          »OÆW¦a°Ïµo¥Í¥½´ÁµÇŦ¯fÅܪº¦¸­n­ì¦]¡C

n          ¬ù¤T¤À¤§¤@ªº¬~µÇ±wªÌ¬O»F¦]©ó¿}§¿¯fµÇ¯fÅÜ (~30%)¡C

n          ¥½´ÁµÇ¯fÅܪº·s¼W¯f¨Ò¤¤¦Ê¤À¤§¤T¤Q¤»»F¦]©ó¿}§¿¯fµÇ¯fÅÜ(35.9%)¡C

n          ¿}§¿¯f¦X¨Ö¥½´ÁµÇ¯f¤ñ¨ä¥L­ì¦]¤Þ°_¤§¥½´ÁµÇ¯f©Ò»Ý¤§¶O¥Î¥­§¡¦h¥X¦Ê¤À¤§¤Q¤G(11.8%)¡C

l          ¿}§¿¯fµÇ¯fÅܪº¯f²z¾Ç¯S¼x¡G¿W¯SªºµÇÂïf²zÅܤÆ-À±º©©Ê¯fÅܤε²¸`©Ê¯fÅÜ (Kimmelstiel Wilson disease)¡F²Ä¤@«¬©M²Ä¤G«¬¿}§¿¯f©Ò³y¦¨ªºµÇ¯fÅÜ¡A¦b¯f²zÅܤƤW¨ÃµL¦W©úÅã®t²§¡A¦ý«áªÌ¦³¸û©úÅ㪺¤p°Ê¯ßµw¤Æ¡C

 

l          ¿}§¿¯fµÇ¯fÅܪº¯f²z¾÷Âà¡G¤åÄm³ø§i»P³J¥Õ¿E¬¡»Ã¯ÀC (protein kinase C)¡B¥Íªø¦]¤l (growth factors): TGF-£]¡B²Ó­M¿E¯À (cytokines): endothelin¡B°ª¦å¿}¡BAdvanced glycosylation end products ( AGE)¡BThe polyol pathway¡B¦å²G´`Àôªº§ïÅÜ¡B¿ò¶Çµ¥¦³Ãö¡C

 

¿}§¿¯fµÇ¯fÅܪº¯fµ{¥i¤À¬°¤­­Ó®É´Á

  • ²Ä¤@´Á¬°°ª¹LÂo´Á: ¦å²G¬y¸gµÇŦ©MµÇµ·²yªº¶q¼W¥[¡AµÇŦ¤j©ó¥¿±`¡C¦³¤@¨Ç¤H¤@ª½°±¯d¦b¥»´Á¡A¦Ó¬Y¨Ç¤H¦b´X¦~«á¶i¦æ¦Ü²Ä¤G´Á¡C
  • ²Ä¤G´Á¬°·L¥Õ³J¥Õ§¿´Á: µÇµ·²y¹LÂo²v¤´¬°ºû«ù¦b¥¿±`­È¤§¤W¡A¦ýµÇµ·²y¶}©l²£¥Í²Ó·L·l¶Ë¡C¤Ö¶qªº¥Õ³J¥Õ·|¬y¥¢¨ì¤p«K¸Ì¡A¦­´Á®É¡A³oºØ·L¥Õ³J¥Õ§¿ªº²{¶H¥i¥H®É¦³®ÉµL¡A¦ý·í¬y¥¢¶q¥Ñ¨C¤ÀÄÁ20²@§J¨ì200²@§J®É(¥¿±`¤H¨C¤ÀÄÁ¥u¦³¤Ö©ó5²@§J¥Õ³J¥Õ±q§¿¤¤¬y¥¢)¡A¦¹¤@²{¶H±N«Ü¤j¥i¯à·|«ùÄò¦s¦b¡C­n°»´ú§¿¤¤·L¥Õ³J¥Õ»Ý°µ¯S§OÀˬd¡A¤£¬O¤@¯ë¥«°âªº¤p«K¸Õ¯È¥i¥H°»´ú±o¨ì¡C¦pªG¿}§¿¯f¤H¯à±±¨î¦åÀ£¤Î¦å¿}¦b¨}¦nªº½d³ò¤º¡A¤£½×¬O¯Ø®q¯À¨Ì¿à«¬©Î«D¨Ì¿à«¬³£¥i¯à°±¯d¦b¥»´Á¼Æ¦~¤§¤[¡C
    • ²Ä1«¬¿}§¿¯f±wµo¯f7.3¦~«á¬ù12.6%·|¶i¤J¥»´Á¡]¼Ú¦{¿}§¿¯f¨Öµo¯g«e¤¬ã¨s¡AEURODIAB¡^¡Aµo¯f18¦~«á¬ù33%·|¶i¤J¥»´Á¡]¤¦³Á¬ã¨s¡^
    • ¦¹®É¤j³¡¥÷¯f±w¤]·|¥X²{¿}§¿¯f²´©³¯fÅÜ
    • ¥Õ³J¥Õ§¿(albuminuria)ªº¿zÀˮɾ÷-¬ü°ê¿}§¿¯f¾Ç·|«Øij
      • ²Ä¤@«¬¿}§¿¯f
        • «C¬K´Á¶}©l¥B¿©¯f®É¶¡¶W¹L5¦~
        • «C¬K´Á«e¤§µo¯f®É¶¡ªøµu»P·L¤p¦åºÞ¨Öµo¯g¦³Ãö
      • ²Ä¤G«¬¿}§¿¯f
        • ­º¦¸¶EÂ_¿}§¿¯f®É
      • ­Y¬°³±©Ê«h¨C¦~ÀË´ú¤@¦¸
      • ­Y¬°¶§©Ê«h©ó6­Ó¤ë¤º¦A½ÆÀ˨⦸
    • ¥Õ³J¥Õ§¿(albuminuria)¿zÀ˪º¹êÅç«Ç¤èªk
      • ¥ô¤@¦¸¤p«Kªºalbumin-to-creatinine ratio
      • ¥H²M±á²Ä¤@¦¸¤p«K¬°¨Î
      • ¦P¤@®É¬q¡A¦h¦¸ÀË´ú ¡C
      • 24¤p®É¤p«Kªºalbumin ©M creatinineÁ`¶q
      • ¤@¬q®É¶¡¤º¤p«KÁ`¶q©Ò§t¤§albumin (¦p4-h overnight)
    • ¼W¥[¥Õ³J¥Õ§¿µ{«×ªº¦]¯À¡G¦å¿}¤É°ª¡A¹B°Ê¡B§¿¸ô·P¬V©Î¦å§¿¡B°ª¦åÀ£¡B¤ßŦ°IºÜ¡B«æ©Ê°ª¿Nµ¥¡C
    • «Ü¦h¾ÇªÌ«Øij¡A¦b¿}§¿¯fµÇ¯fÅܶEÂ_¤Î¶}©l¨Ï¥ÎACEIªvÀø«á¡AÄ~ÄòºÊ´ú§¿¤¤¥Õ³J¥Õ¿@«×¥H°µ¬°ªvÀø®ÄªGµû¦ô¤ÎµÇ¯fÅܶi®i¤§°Ñ¦Ò¡A¦ý¦¹¤@Æ[ÂI¤´¦³«ÝÅçÃÒ¡C
    • µÇ¥\¯àªºµû¦ô¹ï¿}§¿¯fµÇ¯fÅܶi®i¦³¨ä¬Û·íªº­«­n©Ê
  • ²Ä¤T´Á¬°Á{§É¥Õ³J¥Õ§¿´Á:¦¹®É§¿¤¤¥Õ³J¥Õ¬y¥¢²v¤j©ó¨C¤ÀÄÁ200²@§J®É¡A¥Î¤@¯ëªº§¿²G¸Õ¯È§Y¥i°»´ú¨ì¡A¥¿¦¡¶i¤J¿}§¿¯fµÇ¯fÅÜ´Á¡C³o®É¦³¤@¨Ç¯f¤H·|²£¥Í°ª¦åÀ£¡A¶i¦Ó¹ïµÇµ·²y²£¥Í¶Ë®`¡CµM«áµÇŦ³vº¥ªº¥¢¥h¹LÂo¼oª«ªº¯à¤O¡A¦Ó³y¦¨¦å¤¤§¿¯À´á¤Î¦Ù»Ä¤zªº¤W¤É¡C¤GÃþªº¿}§¿¯f¯f±w¥ç¥i¯à°±¯d¦b¥»´Á¼Æ¦~¤§¤[¡C
  • ²Ä¥|´Á¬°¶i¶¥©ÊÁ{§ÉµÇ¯fÅÜ´Á¡CµÇµ·²y¹LÂo²v§C©ó¨C¤ÀÄÁ75ml¡A¨Ã¦³¤j¶qªº³J¥Õ§¿¡C°ª¦åÀ£´X¥Gµo¥Í¦b©Ò¦³¯f¤H¨­¤W¡A¦Ù»Ä¤z¤Î¦å¤¤§¿¯À´á¤W¤É§ó¦h¡C
  • ²Ä¤­´Á¬°¥½´ÁµÇŦ¯fÅÜ´Á¡AµÇµ·²y¹LÂo²v§C©ó¨C¤ÀÄÁ10ml¡AµÇ°IºÜªº¯gª¬²£¥Í¡A»Ý­n¾a¬~µÇ¤~¯à¥Í¦s¡C

 

  • ¿}§¿¯fµÇ¯fÅܪºªvÀø
    • ÄY®æ¦å¿}±±¨î·|©úÅã­°§Cµo¥Í¥Õ³J¥Õ§¿(microabluminuria)¤Î©úÅãµÇ¯fÅÜ (overt nephropathy)ªº¦MÀI©Ê
    • ¬ü°êDCCT¬ã¨sÅã¥Ü: ÄY®æ¦å¿}±±¨î¥i­°§C·L¥Õ³J¥Õ§¿ (microalbuminuria) ªºµo¥Í¹F39%¡A¥Õ³J¥Õ§¿ (albminuria) ªºµo¥Í¹F 54%¡C
    • ­Y¦³¿}§¿¯f¦X¨Ö°ª¦åÀ£¡A¤£½×¦¬ÁY©Ê©ÎµÎ±i©Ê°ª¦åÀ£¬Ò·|¨Ï¿}§¿¯fµÇ¯fÅÜ´c¤Æ¡A¾A·íªº¦åÀ£±±¨î¥i­°§C¦º¤`²v (type 1: 94 to 45%)¤Î¬~µÇ©Î´«µÇ¤§¾÷²v (type 2: 73 to 31%)
      • ­°¦åÀ£ÃĪ«¤§¨Ï¥Î¦pACEI (angiotension converting enzyme inhibitor)¥i¥H­°§C³J¥Õ§¿µ{«× (type1 ¤Î type 2 DM)¡A©µ½w¿}§¿¯fµÇ¯fÅÜ´c¤Æ³t«× (type1 DM with H/T)¡A¦ý»Ý©w´ÁÀË´úµÇ¥\¯à©M¦å¹[¿@«×¤×¨ä¬O¶}©lªvÀø¤@¶g«á¤Î½Õ¾ã¾¯¶q®É¤Î¤@¦~ÀË´ú¬ù¤T¨ì¥|¡A¤£¾A¥Î¥¥°ü¡C
    • ºû«ù¾A·íÅé­«
    • §Ù·Ï («aª¬°Ê¯ß¯e¯f©M¿}§¿¯fµÇ¯fÅÜ´c¤Æ¤§¥D­n¦MÀI¦]¤l)
    • ¹B°Ê-¼W±j¤ßªÍ¥\¯à¤Î­°§C«aª¬°Ê¯ß¯e¯fªº¦MÀI¡A§ïµ½¨­Åé¹ï¯Ø®q¯À¤§±Ó·P©Ê¡A¥H§C½ÄÀ»©Ê¤Î§C±j«×¹B°Ê¬°©y
    • ´î¤Ö°sºëªºÄá¨ú¶q
    • ­­¨î¯×ªÕ¤ÎÁx©T¾J¤§Äá¨ú-¥Õ³J¥Õ§¿¸g±`¦ñÀHÁ`Áx©T¾J¡B§C±K«×Áx©T¾J¡B¤¤©Ê¯×ªÕ¿@«×ªº¤É°ª¡A¥H¤Î°ª±K«×Áx©T¾Jªº¤U­°¡C
    • ­­¨î¶uÂ÷¤lÄá¨ú¶q2§J / ¨C¤é¡A¯S§O¬O¿}§¿¯fµÇ¯fÅܦX¨Ö°ª¦åÀ£¤Î¤ô¸~ªº¯f¤H
    • ¾A·í³J¥Õ½èÄá¨ú (1)-­­¨î¶¼­¹³J¥ÕÄá¨ú¡A¥i¥H­°§CµÇµ·²y¤ºÀ£¤O(intraglomerular pressure)¤Î¶W¹LÂo(hyperfiltration)¡A©µ½w¼ÆºØµÇŦ¯e¯f¤§´c¤Æ¡A´î½wµÇµ·²yÂX²M²v(glomerular filtration rate)¤§¤U­°³t²v¡A¹ï©ó¿}§¿¯fµÇ¯fÅܬO§_¦³¯q¡A©|¦³ª§Ä³¡C(The Modified Diet in Renal Disease Study)
    • «Øij¿}§¿¯fµÇ¯fÅܱw(overt nephropathy)ªÌ¨C¤é³J¥Õ½èÄá¨ú¶q¬° 0.8 §J/¨C¤½¤çÅé­« ( ¬ù¦û¨C¤éÁ`¼ö¶q~10%)¡A­YµÇµ·²yÂX²M²v¶}©l¤U­°¡A«h«Øij¨C¤é³J¥Õ½èÄá¨ú¶q¬° 0.6 §J/¨C¤½¤çÅé­«¡C¦ý¬O³J¥Õ½èÄá¨ú¡AÀ³µø¾ãÅé¯fªp¦Ò¶q¤Î»PÀç¾i®v°Q½×¡A¥H§KÀç¾i¤£¨}©Î¦ñÀH¦Ù¦×µL¤O¡C
    • §ïµ½«aª¬°Ê¯ß¯e¯f¦MÀI¦]¤l¡A¿}§¿¯f¤Î¥½´ÁµÇ¯f±wªÌ°Ê¯ßµw¤Æ³t«×¤ñ¥¿±`¤H§Ö¡A²Ä¤@«¬¿}§¿¯f¦X¨ÖµÇ¯fÅÜ©M²Ä¤G«¬¿}§¿¯f±wªÌ¡Aµo¥Í¦å¯×²§±`ªº¾÷·|¤ñ¥¿±`¤H°ª¡C°Êª«¹êÅçÃÒ©ú¡A§Q¥Î HMG-CoA reductase inhibitors¡A¥i­°§CÁ`Áx©T¾J¤Î§C±K«×Áx©T¾J¡A¦Ó§ïµ½¥Õ³J¥Õ§¿©M©µ½wµÇµ·²yªº´c¤Æ¡C
  • ¶i¦æ©ÊµÇ¯fÅܤ§³B²z
    • ¬ÛÃö¨Öµo¯g¤§³B²z (e,g., renal osteodystrophy)
      • ­­¨îÆQ¤À¤ÎÁCªºÄá¨ú¡B¨Ï¥Î phosphate binder¡BÁקK nephrotoxic agent (e.g., contrast medium)
    • GFR©úÅã¤U­°¡AÀ³¦Ò¼{ÂशµÇŦ¬ì¶i¤@¨B³B²z¡C